EcoDrugPlus

40s Ribosomal Protein S28

Ensembl ID : ENSMOCG00000010653
Gene Symbol: LOC101982800
2 Cross references
126 Possible Orthologues:

40s Ribosomal Protein S4, X Isoform-Like

Ensembl ID : ENSMOCG00000022546
Gene Symbol: LOC101993488
2 Cross references
196 Possible Orthologues:

5 Hydroxytryptamine (Serotonin) Receptor 4

Ensembl ID : ENSMOCG00000007510
Gene Symbol: HTR4
1 Cross references
200 Possible Orthologues:

5'-Nucleotidase Ecto

Ensembl ID : ENSMOCG00000012249
Gene Symbol: NT5E
3 Cross references
249 Possible Orthologues:

5-Hydroxytryptamine Receptor 1a

Ensembl ID : ENSMOCG00000003283
Gene Symbol: HTR1A
3 Cross references
147 Possible Orthologues:

5-Hydroxytryptamine Receptor 1b

Ensembl ID : ENSMOCG00000007114
Gene Symbol: HTR1B
3 Cross references
245 Possible Orthologues:

5-Hydroxytryptamine Receptor 1f

Ensembl ID : ENSMOCG00000001706
Gene Symbol: HTR1F
3 Cross references
145 Possible Orthologues:

5-Hydroxytryptamine Receptor 2a

Ensembl ID : ENSMOCG00000012645
Gene Symbol: HTR2A
3 Cross references
218 Possible Orthologues:

5-Hydroxytryptamine Receptor 2b

Ensembl ID : ENSMOCG00000013792
Gene Symbol: HTR2B
3 Cross references
204 Possible Orthologues:

5-Hydroxytryptamine Receptor 2c

Ensembl ID : ENSMOCG00000002901
Gene Symbol: HTR2C
3 Cross references
226 Possible Orthologues:

5-Hydroxytryptamine Receptor 3a

Ensembl ID : ENSMOCG00000017513
Gene Symbol: HTR3A
3 Cross references
205 Possible Orthologues:

5-Hydroxytryptamine Receptor 3b

Ensembl ID : ENSMOCG00000007763
Gene Symbol: HTR3B
3 Cross references
174 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).